Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Blood Plasma Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT06550752
What this trial is testing

Erectile Dysfunction Treatment Using Stem Cells

Who this might be right for
Erectile Dysfunction
COR clinic of Regenerative Medicine 30
Early research (Phase 1)Study completedNCT00361049
What this trial is testing

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

Who this might be right for
Cancer
Case Comprehensive Cancer Center 49
Testing effectiveness (Phase 2)Looking for participantsNCT02693535
What this trial is testing

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Who this might be right for
Lymphoma, Non-HodgkinMultiple MyelomaAdvanced Solid Tumors
American Society of Clinical Oncology 4,200
Large-scale testing (Phase 3)Not Yet RecruitingNCT06742138
What this trial is testing

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. 284
Not applicableStudy completedNCT01487031
What this trial is testing

Music Therapy on Nausea and Pain for Autologous Stem Cell

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaHodgkin Lymphoma
Case Comprehensive Cancer Center 108
Not applicableApproved For MarketingNCT05463939
What this trial is testing

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Study completedNCT00081939
What this trial is testing

UARK 2003-33, Total Therapy III

Who this might be right for
Multiple Myeloma
University of Arkansas 303
Large-scale testing (Phase 3)Active Not RecruitingNCT04934475
What this trial is testing

MInimal Residual Disease Adapted Strategy

Who this might be right for
Multiple Myeloma
Intergroupe Francophone du Myelome 791
Testing effectiveness (Phase 2)Looking for participantsNCT04661137
What this trial is testing

Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 96
Not applicableLooking for participantsNCT07774845
What this trial is testing

Platelets and Plasma Lipids Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis

Who this might be right for
Cardio Vascular Disease
University of Sao Paulo 45
Testing effectiveness (Phase 2)WithdrawnNCT01055301
What this trial is testing

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple MyelomaPlasma Cell Myeloma
SWOG Cancer Research Network
Large-scale testing (Phase 3)Study completedNCT02257957
What this trial is testing

Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye

Who this might be right for
Dry EyeSjogren Syndrome
Universidad Nacional de Colombia 30
Large-scale testing (Phase 3)Study completedNCT01497522
What this trial is testing

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Novartis Pharmaceuticals 183
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439123
What this trial is testing

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Very early researchLooking for participantsNCT07085559
What this trial is testing

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Who this might be right for
Multiple Myeloma (MM)Plasma Cell Leukemia (PCL)AL Amyloidosis (AL)
Anhui Provincial Hospital 36
Not applicableStudy completedNCT05335824
What this trial is testing

The Effect of Autologous Platelet Concentrations on Orthodontic Treatment Time

Who this might be right for
Class II Division 1 Malocclusion
Damascus University 60
Large-scale testing (Phase 3)Ended earlyNCT00256776
What this trial is testing

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Who this might be right for
Multiple Myeloma
European Society for Blood and Marrow Transplantation 269
Large-scale testing (Phase 3)Study completedNCT03952091
What this trial is testing

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple Myeloma
TJ Biopharma Co., Ltd. 289
Testing effectiveness (Phase 2)Study completedNCT00006013
What this trial is testing

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT04847050
What this trial is testing

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

Who this might be right for
Solid Tumor MalignancyHematologic MalignancyLeukemia+2 more
National Cancer Institute (NCI) 19
Next Page